Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForCapitalImprovements.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Deferred revenue | 849 | (57) |
| Net cash used in operating activities | (28,856) | (27,630) |
| Cash flows from investing activities: | ||
| Capital expenditures | (10) | (24) |
| Purchases of investment securities | (238,588) | (67,324) |
| Proceeds from sales and maturities of investment securities | 104,625 | 82,142 |
| Net cash (used in)/provided by investing activities | (133,973) | 14,794 |
| Cash flows from financing activities: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's capex?
- Dianthus Therapeutics (DNTH) reported capex of $10K in Q1 2026.
- How has Dianthus Therapeutics's capex changed year-over-year?
- Dianthus Therapeutics's capex decreased by 58.3% year-over-year, from $24K to $10K.
- What is the long-term trend for Dianthus Therapeutics's capex?
- Over 2 years (2021 to 2024), Dianthus Therapeutics's capex has grown at a -71.2% compound annual growth rate (CAGR), from $1.26M to $105K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Dianthus Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude